CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%
Home/Business/Aurobindo Pharma Gains on Lannett Deal, …

Aurobindo Pharma Gains on Lannett Deal, Bajaj Finance Raises ₹1,455 Cr

Business
By ThePip Desk•
Add as a preferred source on Google
A worker in a lab coat, hairnet, mask, and gloves inspects generic drug blister packs and vials on an assembly line.

Worker overseeing generic drug packaging on an assembly line.

Key Highlights

Aurobindo Pharma shares surge on US FTC approval for Lannett acquisition. Bajaj Finance raises ₹1,455 crore via NCDs, boosting its financials.

Aurobindo Pharma Rises on US FTC Nod for Lannett Deal

Aurobindo Pharma’s shares jumped by 1.96% to Rs 1471.40 after its arm secured the US Federal Trade Commission’s (FTC) approval.

This approval is for acquiring 100% membership interest in Lannett, a strategic move set to bolster Aurobindo’s presence in the U.S. generics market. The deal also offers diversification into a specialized, high-value therapeutic category.

  • The stock opened at Rs 1461.95 and touched a high of Rs 1480.00.
  • A total of 109274 shares were traded.
  • The company has a current market cap of Rs 84658.23 crore.

Bajaj Finance Secures
₹1,455 Crore via NCDs

In other corporate news, Bajaj Finance moved up by 0.55% to Rs 964.40.

This gain followed its Debenture Allotment Committee’s approval to raise Rs 1,455.40 crore through Non-Convertible Debentures (NCDs) on June 18, 2026.

  • The scrip opened at Rs 951.65 and traded with a high of Rs 971.10.
  • A total of 304675 shares were traded.
Aurobindo PharmaBajaj FinanceLannettUS FTC